Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Biologic therapy.

Columbia University Medical Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, NY
Treatments:Biologic therapyHospital:Columbia University Medical Center
Drugs:Journal:Link
Date:May 2014

Description:

Patients:
This phase 2 study involved 58 mantle cell lymphoma patients who were previously treated with bortezomib. The median patient age was 68 years years and 77.6% were male.

Treatment:
Patients were treated with the biologic therapy agent everolimus, an inhibitor of the mTOR protein that causes cancer cell death.

Toxicities:
The most severe toxicities were of grade 4 and included neutropenia, thrombocytopenia, and abdominal pain. Grade 3 fatigue and pneumonia were also reported.

Results:
The median overall survival was 16.9 months.

Support:
This study was supported by Novartis Pharmaceuticals.

Correspondence: Dr. Owen A. O’Connor; email: owenoconnor@columbia.edu



Back